Posted On: 09/02/2016 5:57:02 PM
Post# of 405
* INNV was trading steadily at 8 cents awhile back with ~55M outstanding shares and about $1M in Revs rounded-up and looking ahead to 2017, it should come in at $12-13M WITHOUT factoring in OTC Fluticare:
12M x 8 = 96 / 2 (o/s has just about doubled since then) = 48 cents and that is with NO Premium for anticipation of Fluticare FDA approval. So, it is LOGICAL that PPS should be approaching 50 cents soon and not stay in the 20's. Decision will come at some point and every day you are not in could mean MISSING the DOUBLE+ ! Trade wisely folks as market is forward looking.
(Fluticare approval brings $13M in U.S. sales and $6M ish from Int'l during 2017). Just ramps up from there but likely will be bought out before end of 2018 IMO. My target $5.75 - 7
12M x 8 = 96 / 2 (o/s has just about doubled since then) = 48 cents and that is with NO Premium for anticipation of Fluticare FDA approval. So, it is LOGICAL that PPS should be approaching 50 cents soon and not stay in the 20's. Decision will come at some point and every day you are not in could mean MISSING the DOUBLE+ ! Trade wisely folks as market is forward looking.
(Fluticare approval brings $13M in U.S. sales and $6M ish from Int'l during 2017). Just ramps up from there but likely will be bought out before end of 2018 IMO. My target $5.75 - 7
(1)
(0)
